A researcher’s existential crisis led to a scientific breakthrough.

An overabundance of ribosomes drives an imbalance of proteins produced from long and short genetic transcripts in a mouse model of fragile X syndrome.

Activating certain receptors in the amygdala — a treatment that runs counter to a leading theory of what causes the condition — can reverse some traits in rats.

Elizabeth Berry-Kravis has spent decades uncovering molecular clues to fragile X syndrome and crafting trials of treatments. Her efforts are paying off.

Cara Westmark has spent the past year building the case that a drug designed for fragile X syndrome might help coronavirus patients, too.

A gene therapy for Angelman syndrome stands at the forefront of efforts to treat autism-linked conditions that stem from single genes.

Drug after drug has failed in clinical trials for fragile X syndrome. A new study provides an explanation — a decrease in the drugs’ effectiveness over time — and points to a new strategy that could circumvent this problem.

Fragile X syndrome is a leading genetic cause of autism. People who have either condition often share certain traits, such as difficulties in social situations.

Many drugs for fragile X syndrome have failed in large clinical trials, but candidates that target new aspects of the condition may fare better.

Autism and intelligence share genetic variants, researchers grow Neanderthal mini-brains and see overlap with autism, and maternal diabetes is an autism risk factor.